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Post-Endovascular Aneurysm Repair Patient
Outcomes and Follow-up Are Not Adversely Impacted
By Long Travel Distance to Tertiary Vascular Surgery
Centers
Mark Langsfeld, John Marek, Dusadee Sarangarm
University of New Mexico Division of Vascular Surgery, Albuquerque, NM
Objective: To determine if patient adherence to follow-up and patient outcomes after
endovascular aneurysm repair (EVAR) are impacted by the distance a patient lives from a
tertiary care treatment center.
Methods: A retrospective review of 136 consecutive patients undergoing EVAR at the New
Mexico VA Medical Center over a seven year period was conducted. Follow-up occurred with
clinic visits and computed tomography scans at one month post-discharge, every six months for
two years, and then yearly. Patients were stratified as living within a 100 mile radius of the
treatment center (Group 1) versus those living outside this radius (Group 2). Patients were
defined as having inadequate follow-up if two or greater consecutive appointments were missed.
Survival and graft-related complication rates were analyzed for both patient groups.
Results: Operative mortality was 0.74% and the overall mean follow-up time was 52.1±25.9
months in 136 patients. Ten patients were not analyzed due to mortality less than one year from
the EVAR procedure. Of the 126 patients eligible for the study, 19 (15%) had inadequate followup, as defined by missing two or more appointments. Approximately 44% (60/136) of patients
lived within a 100 mile radius of the treatment center (Group 1) versus 56% (76/136) of patients
living outside this 100 mile radius (Group 2). There was no difference in the adequacy of followup in Group 1 versus Group 2 patients (14.5% vs. 13.3%, P=1.0). The incidence of major
complication defined as aneurysm rupture or conversion to open repair was not statistically
different in Group 1 versus Group 2 patients (5.0% vs. 11.8%, P=0.23). Five patients (3.7%) died
due to AAA-related late causes (2 in Group 1 vs. 3 in Group 2).
Conclusions: Recent studies have demonstrated higher catastrophic graft complications in
patients with inadequate follow-up after EVAR. As many of these procedures are being
performed at tertiary referral care centers, many patients are required to travel a long distance for
their procedure and follow-up tests. Our study indicates that distance from a tertiary care center
is not a limiting factor in patient adherence to follow-up, patient graft-related morbidity or
patient survival.

INTRODUCTION
Following the introduction of endovascular
aneurysm repair (EVAR) by Parodi and
associates in 1991, EVAR has become the
procedure of choice for many patients for
repair of abdominal aortic aneurysms (AAA).1,
2
Currently, four FDA approved endografts are
on
the
market:
Medtronic
AneuRx
(Minneapolis,
Minn),
Gore
Excluder
(Flagstaff, Ariz), Endologix PowerLink
(Irvine, Calif) and Cook Zenith (Bloomington,
Ind).
Reported advantages of the endovascular
approach as compared to traditional open
repair are reduced blood loss, shorter hospital
stays, increased likelihood of discharge to
home, less cardiovascular morbidities and
decreased peri-operative mortality.3-8 Concerns
regarding this procedure include a substantial
increase in healthcare costs, with questionable
long-term benefits in mortality, morbidity and
quality of life.9-15 Moreover, EVAR has been
shown to have a higher rate of graft-related
complications which require reintervention
compared to open repair.16-18 Due to this high
rate of reintervention, endograft patients must
be monitored for life with radiologic studies,
thus emphasizing the critical importance of
long-term follow-up for this patient
population.
Though clinical trials have shown EVAR
and open repair to have comparable outcomes,
these trials are performed under conditions that
are unlikely to be achieved in general surgical
practice. Resources available at a tertiary care
center in a clinical trial setting, such as
specially recruited research nurses and staff to
ensure the completeness of patient follow-up,
are frequently unavailable to surgeons in
private practice. This raises concerns regarding
the completeness of follow-up for the majority
of AAA patients and thus, the success of
EVAR in terms of long-term patient outcomes.
A recent study has shown that post-EVAR
patients with incomplete follow-up have

higher fatal complication rates in comparison
to patients with frequent follow-up.19
Given the significance of follow-up for
EVAR patients, it is imperative to understand
the factors which impede good adherence to
follow-up regimens. Studies into the
determinants of patient adherence have shown
them to be multi-factorial and inconsistent.
Some causes of poor patient adherence include
patient lack of understanding, inability to
comply due to financial, physical or
physiologic reasons, long waiting times at
clinics
and
long
times
between
appointments.20, 21 For our local VA Medial
Center (VAMC), patients are referred from
rural areas in three surrounding states for
treatment of AAA’s, thus raising concerns for
potential poor patient follow-up due to the
long distances patients must travel. The
purpose of our study was to test the following
hypotheses in a VA patient population:
•
Follow-up adherence post-EVAR is
superior for patients living close to the
VAMC than for those traveling long
distances.
•
Outcomes for patients with incomplete
follow-up are inferior to patients with
complete follow-up.
•
Outcomes for patients living within 100 mi
of Albuquerque are better than for patients
living outside of this radius.
METHODS
Our
hypotheses
were
tested
by
retrospectively reviewing the results of 136
consecutive EVAR’s performed at the
Albuquerque VAMC from October, 1999 to
April, 2006. Of these 136 patients, 126
patients survived the first year after EVAR and
were therefore eligible for follow-up. Thus,
data for the group of 126 patients was used for
follow-up analyses, while data for the entire
series was used for the analyses of distance
from Albuquerque. Table I and II summarize
the demographics of the entire series and of
the 126 patients who were eligible for follow-

Table I: Demographics for the 136 patients in the series
Demographics
Value, n
Age (median ± SD)

72 ± 7.7

AAA size (mean ± SD)

5.7 ± 1.2

Patients living within 100mi
of Albuquerque

44.1%

Treated emergently

6

Treated electively

130

Treated in industry sponsored
clinical trial

12

Treated in routine practice

114

Prosthesis used
AneuRx*

115

¥

13

Ancure

Excluder

†

Endologix

7
‡

1

*Medtronic AneuRx (Minneapolis, Minn)
¥Guidant Ancure (Indianapolis, Ind)
†Gore Excluder (Flagstaff, Ariz)
‡Endologix PowerLink (Irvine, Calif)
Table II: Demographics of follow-up eligible patients
Demographics

Value, n

Age (median ± SD)

71 ± 7.8

AAA size (mean ± SD)

5.7 ± 1.1

Patients living within 100mi
of Albuquerque

43.7%

Treated emergently

6

Treated electively

120

Treated in industry sponsored
clinical trial

11

Treated in routine practice

115

Prosthesis used
AneuRx*

112

¥

13

Ancure

Excluder

†

Endologix

5
‡

1

*Medtronic AneuRx (Minneapolis, Minn)
¥Guidant Ancure (Indianapolis, Ind)
†Gore Excluder (Flagstaff, Ariz)

‡Endologix PowerLink (Irvine, Calif)

up, respectively.
All patients who were symptomatic or
whose aneurysms were > 5cm were evaluated
for repair. Patients with favorable anatomy
including a proximal infrarenal neck ≥ 15mm;
an aortic neck luminal diameter ≤ 26mm;
aortic angulation ≤ 60º; and common iliac
arteries without excessive tortuosity for
proximal and distal fixation of an endograft
were offered EVAR. Female patients were
excluded from the study due to low sample
size; only one female patient was treated
during the study period. Procedures were
performed using a bilateral, transfemoral
approach, with intravascular ultrasound and
angiography to confirm technically successful
graft
placement.
Attending
physician
preference determined the type of graft used.
All procedures were performed by fellowship
trained vascular surgeons in an endovascular
operating room suite with fixed imaging.
At the time of their procedure, all patients
were prospectively enrolled in a vascular
database. Starting in 1999, our VA started
participating in the OVER trial (Open versus
Endovascular Repair), a national VA study
comparing open vs. EVAR repair of
abdominal aneurysms. Of note, the
postoperative follow-up regimen was the
similar for both study and non-study patients,
thereby reducing the statistical effects of this
confounding factor. Both groups of patients
were followed by the same research nurse,
who coincidently managed both study patients
and non-study patients.
For all patients, missed appointments were
documented in the VAMC electronic database
and were rescheduled by a research nurse. If
verbal contact via telephone was not made,
several telephone messages were left regarding
the missed appointment and need to
reschedule. If repeated telephone attempts
failed to reach the patient, a letter was mailed
to the permanent home address listed in the
VAMC electronic database. If this method of
contacting the patient was unsuccessful, no

further attempt was made to contact the patient
directly. At this point, a note was entered into
the electronic record to contact the
Albuquerque vascular group should anyone in
the VAMC system make contact with the
patient. Follow-up did differ, however, in that
the management of study patients included
more frequent telephone contact and stricter
monitoring of follow-up compliance when
compared to non-study patients.
All patients were followed with an office
visit and imaging at one month, every six
months for two years and then yearly for life.
The imaging modalities used were plain
abdominal radiographs (flat, upright, lateral
and oblique) and computed tomography (CT)
with angiography; duplex ultrasound or noncontrast CT were utilized in place of CT with
angiography when patient comorbidities (i.e.
renal insufficiency) prohibited the use the
contrast. The need for consistent follow-up
and the risks associated with EVAR were
stressed to each patient before discharge by
staff and the attending physician.
For the purposes of this study, we defined
incomplete follow-up as any patient who
missed more than two consecutive follow-up
office visits at the Albuquerque VAMC. All
other patients were defined as having frequent
follow-up. We also arbitrarily assigned
patients living “close” to the VAMC as within
a 100mi radius, and those living far as outside
this radius. Next, we retrospectively reviewed
the electronic charts of all 126 patients to
determine their follow-up status. Electronic
charts at not only the Albuquerque VAMC, but
also at remote VAMC’s throughout the United
States were reviewed. This resulted in reestablishment of contact with all but five of the
19 patients lost to follow-up. In the absence of
definitive evidence of mortality or known
complications, these five patients were
included in the analysis and assumed to be
alive and complication free.
The outcomes examined in our study were
overall survival, subsequent need for minor

surgical
reintervention
(all
surgical
interventions excluding conversion to open
repairs) and subsequent need for major
reintervention, defined as conversion to open
repair.
To calculate survival time and time to
initial minor reintervention, Kaplan-Meir life
table analyses were performed. Log-rank tests
were used to assess the difference between
these curves. Differences in distributions were
assessed using Wilcoxon Rank Sum test and
differences in categorical variables were
assessed using Fisher’s Exact test. Data was
analyzed using SAS 9.1 software (SAS, Inc,
Cary, NC). P values < 0.05 were considered
indicative of statistical significance.
RESULTS
The overall mean follow-up time for the
series was 52.1 ± 25.9 months; the median was
52.9 months with a minimum of 2 days and a
maximum of 94.5 months. No patients had
EVAR less than one year at the conclusion of
this study. For the entire series, 34 patients
required 52 minor surgical reinterventions
(angio, n = 8; coiling for Type II endoleak, n =
16; proximal/distal cuff, n = 13; stent, n = 3,
bypass, n = 4; miscellaneous interventions, n =
8), 12 patients required major surgical
reintervention defined as conversion to open
repair and one patient needed conversion to
open repair, but declined the procedure. The
types of devices used and major complications
by device are summarized in Table III.
Of the patients who underwent open repair
subsequent to EVAR, three resulted in death.
Two open repair patients experienced
incomplete follow-up at the Albuquerque
VAMC, one declined follow-up and the other
relocated; both patients were repaired at an
outside facility and survived their open repair.
Additionally, both also lived outside a 100mi
radius of Albuquerque. Table IV summarizes
the patients who required conversion to open
repair and their outcomes.

Table III: Types of devices and number of complications by device
Follow-up, n (%)
Patient total
AneuRx

*

¥

Ancure

Excluder

†

Endologix

‡

Frequent

Incomplete

< 100 mi of VAMC,
n (%)

> 100 mi of VAMC,
n (%)

Open conversion,
n (%)

107

19

60

76

12

89 (83.2)

18 (94.7)

49 (81.7)

66 (86.8)

10 (83.3)

12 (11.2)

1 (5.3)

6 (10.0)

7 (9.2)

1 (8.3)

5 (5.7)

0 (0.0)

5 (8.3)

2 (2.6)

1 (8.3)

1 (0.9)

0 (0.0)

0 (0.0)

1 (1.3)

0 (0.0)

*Medtronic AneuRx (Minneapolis, Minn)
¥Guidant Ancure (Indianapolis, Ind)
†Gore Excluder (Flagstaff, Ariz)

‡Endologix PowerLink (Irvine, Calif)
Table IV: Major complications
Complications

Months after
EVAR

Intervention

RUPTURED L
EXTERNAL ILIAC

0

Open

POST-OP OCCLUSION

1

Open

INFECTED GRAFT

12

Open

EXPANDING AAA

25

Open

INFECTED GRAFT

32

Open

RUPTURED AAA

45

Open

GRAFT MIGRATION

48

Open

RUPTURED AAA

50

Open

ENLARGING
PROXIMAL AAA
ILIAC PERF DURING
ATTEMPTED
PLACEMENT OF RIGHT
ILIAC STENT GRAFT

69

Open

79

Open

ENLARGING AAA

unknown*

Open

RUPTURED AAA

unknown*

Open

Location of
Reintervention
Albuquerque
VAMC
Albuquerque
VAMC
Albuquerque
VAMC
Albuquerque
VAMC
San Antonio
VAMC
Albuquerque
VAMC
Albuquerque
VAMC
Albuquerque
University
Hospital
Albuquerque
VAMC
Albuquerque
VAMC
Lubbock
VAMC
Dallas VAMC

*Unable to determine the exact date of operation in electronic chart.

Follow-up
Status

Reason for
Incomplete
Follow-up

Outcome

Frequent

Death

Frequent

Survived

Frequent

Survived

Frequent

Survived

Incomplete

DECLINED

Survived

Frequent

Death

Frequent

Survived

Frequent

Survived

Frequent

Survived

Frequent

Death

Frequent

Survived

Incomplete

RELOCATED

Survived

Table V: AAA-related mortality
Mechanism

Months after
EVAR

Follow-up
status

Location of
residence at
time of EVAR

Miles from
Albuquerque

COMPLICATIONS OF CIRRHOSIS, LEADING TO
COAGULOPATHY WITH CONSEQUENT ENDOLEAK

12.69

FREQUENT

ALBUQUERQUE,
NM

0

COMPLICATIONS OF OPEN REPAIR OF INFECTED ELG

13.25

FREQUENT

BIG SPRING, TX

416

COMPLICATIONS OF RIGHT LOWER EXTREMITY
ISCHEMIA WITH THROMBOSIS OF RIGHT LIMB OF
ENDOGRAFT

2.37

FREQUENT

LOS LUNAS, NM

23

PERI-OPERATIVE COMPLICATIONS OF EVAR

0.07

FREQUENT

ALBUQUERQUE,
NM

0

COMPLICATIONS OF TRACHEOTOMY STATUS POST
CONVERSION TO OPEN REPAIR

46.98

FREQUENT

DEMING, NM

233

Five patients died due to AAA-related
causes (3.7%), three of whom required open
repair subsequent to EVAR and died from
complications thereof. One patient died within
one month of EVAR. None of these patients
experienced incomplete follow-up. Three
patients lived outside of Albuquerque. Table V
delineates the cause of death for each case
According to the study definition, 107
(85.0%) of 126 patients achieved frequent
follow-up, and 19 (15.0%) received
incomplete follow-up. After one year, the
mean follow-up for the 107 patients in the
frequent follow-up group was 41.4 ± 23.0
months, while the mean follow-up in the
incomplete follow-up group was 57.5 ± 19.7
months (P = 0.004). For the incomplete
follow-up group, the median month of the first
missed appointment was 36 ± 19.0 months
with a minimum of one month and a maximum
of 60 months. Most patients in the incomplete
follow-up group underwent EVAR during
2000-2002, while patients in the frequent
follow-up group are more evenly distributed in
time (Table VI). Five of the 19 patients who
experienced incomplete follow-up were not
seen subsequently at another VA with CT
imaging of their AAA. One patient (Patient
#50) in the study failed to keep at least one
follow-up appointment due to a psychiatric
condition. Table VII summarizes the patients
in the incomplete follow-up group and their
follow-up status within the VAMC system.

Table VI: Distribution of patients by year of EVAR and
follow-up status
Frequent follow- Incomplete
EVAR year
up
follow-up
1999

8

1

2000

31

7

2001

27

3

2002

9

6

2003

14

1

2004

20

1

2005

6

0

2006

26

0

Total

117

19

The mean follow-up time for patients
living within 100mi of Albuquerque was not
statistically different from those living outside
a 100mi radius at (53.7 ± 28.3 months vs. 50.9
± 24.0 months; P = 0.47). Frequent follow-up
was achieved in 52 (86.7%) of the 60 patients
living within 100mi of Albuquerque, while
eight (13.3%) patients received incomplete
follow-up. Of the 76 patients living outside a
100mi radius of Albuquerque, 65 (85.5%)
achieved frequent follow-up and 11 (14.5%)
experienced incomplete follow-up. There was
no difference in the percentage of incomplete
follow-up patients for those living close vs.
those living far (P = 1.0). For the 11 patients
living outside a 100mi radius of Albuquerque
who experienced incomplete follow-up, only

Table VII: Incomplete follow-up patients
Patient
#

Location of residence at
time of EVAR

Miles from
Albuquerque

Months after EVAR of
first missed appointment

Reason for incomplete
follow-up

Seen at
another VAMC

Months before AAA size
documented at another VAMC

3

ALBUQUERQUE, NM

0

3

NON-COMPLIANT

YES

29

10

ALBUQUERQUE, NM

0

30

RELOCATED

YES*

17

ALBUQUERQUE, NM

0

36

DECLINED

NO

20

COLORADO CITY, TX

434

42

MEDICAL

NO

27

BORGER, TX

340

30

RELOCATED

YES*

30

ALBUQUERQUE, NM

0

48

NON-COMPLIANT

NO

32

MIDLAND, TX

413

48

DECLINED

YES

24

35

SANTA FE, NM

64

36

RELOCATED

YES

0

50

ALBUQUERQUE, NM

0

1

PSYCHIATRIC

NO

60

MUNDS PARK, AZ

341

66

DECLINED

YES*

67

AMARILLO, TX

287

36

RELOCATED

YES*

83

FOUNTAIN, CO

366

3

RELOCATED

YES*

86

SUNRAY, TX

311

42

RELOCATED

YES

12

88

SAN ANGELO, TX

502

12

DECLINED

YES

18

89

AMARILLO, TX

287

42

FINANCIAL/BENEFITS

NO

91

ALBUQUERQUE, NM

0

12

RELOCATED

YES*

92

ODESSA, TX

402

54

MEDICAL

YES*

103

ALBUQUERQUE, NM

0

12

FINANCIAL/BENEFITS

YES*

128

AMARILLO, TX

287

18

MEDICAL

YES

0

*Documented CT imaging at another VA, but no record of AAA size

two were not subsequently seen at another VAMC with CT
imaging of their AAA’s. The closest of these 11 patients to the
Albuquerque VAMC was 287mi and the furthest was 502mi. For
the eight patients living within a 100mi radius of Albuquerque

who experienced incomplete follow-up, seven lived within
Albuquerque and one lived 64mi from Albuquerque.
Comparing the outcomes of patients living within and outside
100mi radius of Albuquerque, no statistical difference was found
in survival (Fig 1) or rate of reintervention (Fig 3). The incidence
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Fig 1: Survival for patients living outside a 100mi radius of Albuquerque (solid
line) vs. those living within a 100mi radius of Albuquerque (dashed line)
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Fig 3: Reintervention for patients living outside a 100mi radius of Albuquerque
(solid line) vs. those living within a 100mi radius of Albuquerque (dashed line)
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Fig 2: Survival for patients with frequent follow-up (solid line) vs. those with
incomplete follow-up (dashed line)
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Fig 4: Reintervention for patients with frequent follow-up (solid line) vs. those with
incomplete follow-up (dashed line)

of major complication was greater in the group
living outside a 100mi radius of Albuquerque
compared to those living within the radius
though this was not statistically significant at
11.8% (n = 9) vs. 5.0% (n = 3; P = 0.23).
Comparing the outcomes of patients with
incomplete follow-up and frequent follow-up,
no statistical difference was found in survival
(Fig 2) or rate of reintervention (Fig 4). The
incidence of major complication or conversion
to open repair, was similar in both groups, at
10.5% (n = 10) for the frequent follow-up
group vs. 9.3% (n = 2; P = 1.0) for the
incomplete follow-up group. The two patients
who required open repair in the incomplete
follow-up group both lived outside a 100mi
radius of Albuquerque at 334 miles and 502
miles.
DISCUSSION
EVAR has increasingly become the
operation of choice to treat AAA’s due to
benefits in peri-operative mortality, shorter
hospital stays and decreased morbidity.3-8
Despite these benefits, EVAR has not been
shown to be superior to open repair in terms of
long-term AAA-related mortality, perceived
patient quality of life and healthcare costs.9-15
Additionally, EVAR patients are more likely
to suffer from long-term complications, such
as endoleak, graft migration and increasing
aneurysmal size, thus necessitating life-time
follow-up with radiologic imaging for these
patients.16-18
Though EVAR and open repair have been
shown to achieve comparable long-term
outcomes in clinical trials, these results are
achieved with resources that may not be
available to a community surgeon in private
practice. Even with these resources, clinical
trials such as the European Collaborators on
Stent-Graft Techniques for AAA and Thoracic
Aortic Aneurysm and Dissection Repair
(EUROSTAR) trial, a large multi-center study
of 4433 patients, have reported percentages as

high as 35% of patients not completing all
scheduled appointments.22
Recently, a study by Jones et al. comparing
the outcomes of patients in industry sponsored
clinical trials with non-study patients has
shown no difference in patient survival and
reintervention rate.19 Similar to the
EUROSTAR trial, this study reported that
33% of EVAR patients had incomplete followup. Data from this study has also demonstrated
that post-EVAR patients with incomplete
follow-up have higher fatal complication rates
than patients with frequent follow-up. This
study suggests it is imperative to understand
the determinants of consistent patient
adherence to follow-up regimens in order to
improve EVAR patient outcomes.
One area of concern at the Albuquerque
VAMC is the distance patients have to travel
for follow-up appointments. The Albuquerque
VAMC is a tertiary care facility with a large
catchment area, serving veterans in New
Mexico, east Texas, southern Colorado and
western Arizona. With at least six months
between each appointment and possibly
hundreds of miles to travel, several barriers
exist to patient adherence to follow-up
appointments. Based on these factors and on
literature review, we formed three hypotheses:
•
Follow-up adherence post-EVAR is
superior for patients living close to the
VAMC than for those traveling long
distances.
•
Outcomes for patients with incomplete
follow-up are inferior to patients with
complete follow-up.
•
Outcomes for patients living within 100 mi
of Albuquerque are better than for patients
living outside of this radius.
In reviewing the first hypothesis, we found
no significant difference in follow-up
adherence for patients living within a 100mi
radius of Albuquerque versus those living
outside this radius. Like the determinants of
adherence, we believe the reasons behind this
result are multifactorial. First, we believe the

national VAMC network is an ideal system for
follow-up of EVAR patients regardless of their
distance from a tertiary care facility because it
eliminates many of the barriers to patient
adherence. One major advantage to this system
is an electronic database, which can track
patients at any facility in the country. Factors,
such as notes left on the system to contact the
Albuquerque VAMC should any other VAMC
make contact with the patient, likely contribute
to improved patient follow-up. Another
possible reason why distance did not
significantly affect the follow-up adherence is
that once patients are plugged into the VAMC
system in terms of benefits, their healthcare
costs are covered in ways that patients in the
general public are not. This eliminates yet
another stressor that impedes patient
adherence. Lastly, the VAMC is a national
system, making it easier for a patient to be
seen anywhere in the country; once a patient is
seen, providers are able to look at notes in the
electronic database and encourage patients to
attend their missed appointments. Of the 19
patients in the infrequent follow-up group at
the Albuquerque VAMC, only 5 were not
actually seen at another VAMC.
In examining the second hypothesis we
demonstrated no difference in survival or
reintervention rate for patients with frequent or
incomplete follow-up. Because only 15% of
patients experienced incomplete follow-up, we
believe our sample size was too small to
discern a difference in outcomes. In fact,
patients had longer follow-up times in the
infrequent follow-up group than in the
frequent follow-up group. This may be due to
our inability to re-establish contact with five of
the 19 patients in this group and our
assumption then that these five patients are
alive and well. In actuality, given that 40.4%
of patients in the study died during the study
period from all-cause mortality, some of these
patients were likely deceased and may have
made a difference in the survival and
reintervention rate of the infrequent follow-up

group. Another reason why the follow-up time
was longer for infrequent follow-up patients
was due to the fact that most of these patients
had EVAR in 2000-2002 and none in 20052006, while the frequent follow-up patients
were evenly distributed in time. In other
words, EVAR’s performed in more recent
years likely artificially lowered the follow-up
time for the frequent follow-up patients.
Looking at the third hypothesis we found
no difference in survival or reintervention rate
for patients living within a 100mi radius of
Albuquerque compared to those living outside
this radius. This concurs with our analyses that
there was no difference in the degree of
follow-up between these two groups.
Overall, these results suggest that distance
from a tertiary care center is not a limiting
factor in patient adherence to follow-up
protocols. In addition, the VA medical system
is equipped with a comprehensive electronic
records database and fewer economic barriers
for patients to obtain healthcare. Our study
also implies that such a system can much
improve follow-up in EVAR patients. We
achieved a percentage of patients with
incomplete follow-up that is less than half of
the rate published in current literature.
Interestingly, this did not translate to improved
patient outcomes, though this may be due to a
sicker veteran population compared to the
general public.23
Our study has both strong points and
limitations in methodology. One of the
strengths of this paper is the long duration of
study, with median follow-up time at over four
years. Only two patients of the 34 who
required reintervention had a secondary
procedure done at greater than four years from
the initial EVAR and no patients who expired
from a AAA-related cause died later than four
years from the initial EVAR. This suggests
that the study was conducted for a sufficient
duration of time as to discover most of the
outcomes data. Furthermore, at the conclusion
of this study, all patients were at least one year

out from the date of the initial EVAR
procedure. This is significant because our
definition of infrequent follow-up required
patients to miss greater than two appointments
which was not possible within a one year
period (one month and six month
appointments); in other words, if our study had
included patients who were less than one year
out from EVAR, the number of patients in the
frequent follow-up group would be falsely
elevated. Another asset to this study is the
dedicated nurse who vigilantly and persistently
followed patients, regardless of whether they
were enrolled in a clinical trial until absolutely
all methods of contact were exhausted. This
likely contributed to the lower percentage of
patients in the infrequent follow-up group.
Potential limitations of this study include
the biases inherent in retrospective studies and
the low sample size which may contribute to
type II statistical errors. We assumed the data
in the VAMC system was up to date and
complete in terms of outcomes, and therefore
did not attempt to re-establish direct contact
with the patients in the infrequent follow-up
group or seek other means of determining their
mortality status (i.e. mortality databases,
obituaries, etc.), which could also be a
limitation. Lastly, the results obtained were
relevant for a veteran population and may not
apply to the general patient population. Further
studies on the determinants for poor patient
adherence to follow-up protocols and the
impact of follow-up on patient outcomes
should be conducted at other institutions to
corroborate our findings.
CONCLUSION
At the Albuquerque VAMC, one in seven
EVAR patients have incomplete follow-up.
Moreover, even though more than half of our
patient population lives outside a 100mi radius
of the VAMC, no difference was found in
follow-up adherence between these two
groups. Consequently, no difference in
outcomes was demonstrated based on patient

follow-up status or distance from the tertiary
care center. This suggests that patients can be
safely treated for EVAR at tertiary care centers
which are a long distance from home, and
achieve reliable follow-up. Additional studies
evaluating the potential barriers against patient
adherence to follow-up regimens are needed in
order to help in the selection of good
candidates for EVAR.
REFERENCES
1.
2.

3.

4.

5.

6.

7.

8.

9.

Parodi JC, Palmaz JC, Barone HD. Transfemoral
intraluminal graft implantation for abdominal aortic
aneurysms. Ann Vasc Surg. 1991;5:491-499.
Veith FJ, Marin ML, Cynamon J, Schonholz C,
Parodi J. 1992: Parodi, Montefiore, and the first
abdominal aortic aneurysm stent graft in the United
States. Ann Vasc Surg. 2005;19:749-751.
Bush RL, Johnson ML, Collins TC, et al. Open
versus endovascular abdominal aortic aneurysm
repair in VA hospitals. J Am Coll Surg.
2006;202:577-587.
Bush RL, Johnson ML, Hedayati N, Henderson
WG, Lin PH, Lumsden AB. Performance of
endovascular aortic aneurysm repair in high-risk
patients: Results from the veterans affairs national
surgical quality improvement program. J Vasc
Surg. 2007;45:227-233; discussion 233-5.
Chahwan S, Comerota AJ, Pigott JP, Scheuermann
BW, Burrow J, Wojnarowski D. Elective treatment
of abdominal aortic aneurysm with endovascular or
open repair: The first decade. J Vasc Surg.
2007;45:258-62; discussion 262.
Dillavou ED, Muluk SC, Makaroun MS. Improving
aneurysm-related outcomes: Nationwide benefits of
endovascular repair. J Vasc Surg. 2006;43:446-51;
discussion 451-2.
Greenhalgh RM, Brown LC, Kwong GP, Powell
JT, Thompson SG, EVAR trial participants.
Comparison of endovascular aneurysm repair with
open repair in patients with abdominal aortic
aneurysm (EVAR trial 1), 30-day operative
mortality results: Randomised controlled trial.
Lancet. 2004;364:843-848.
Lee WA, Carter JW, Upchurch G, Seeger JM,
Huber TS. Perioperative outcomes after open and
endovascular repair of intact abdominal aortic
aneurysms in the United States during 2001. J Vasc
Surg. 2004;39:491-496.
Aljabri B, Al Wahaibi K, Abner D, et al. Patientreported quality of life after abdominal aortic
aneurysm surgery: A prospective comparison of
endovascular and open repair. J Vasc Surg.
2006;44:1182-1187.

10. EVAR trial participants. Endovascular aneurysm
repair versus open repair in patients with abdominal
aortic aneurysm (EVAR trial 1): Randomised
controlled trial. Lancet. 2005;365:2179-2186.
11. EVAR trial participants. Endovascular aneurysm
repair and outcome in patients unfit for open repair
of abdominal aortic aneurysm (EVAR trial 2):
Randomised
controlled
trial.
Lancet.
2005;365:2187-2192.
12. Lottman PE, Laheij RJ, Cuypers PW, Bender M,
Buth J. Health-related quality of life outcomes
following elective open or endovascular AAA
repair: A randomized controlled trial. J Endovasc
Ther. 2004;11:323-329.
13. Prinssen M, Buskens E, de Jong SE, et al. Costeffectiveness of conventional and endovascular
repair of abdominal aortic aneurysms: Results of a
randomized trial. J Vasc Surg. 2007;46:883-890.
14. Soulez G, Therasse E, Monfared AA, et al. Pain
and quality of life assessment after endovascular
versus open repair of abdominal aortic aneurysms
in patients at low risk. J Vasc Interv Radiol.
2005;16:1093-1100.
15. Wilt TJ, Lederle FA, Macdonald R, Jonk YC,
Rector TS, Kane RL. Comparison of endovascular
and open surgical repairs for abdominal aortic
aneurysm. Evid Rep Technol Assess (Full Rep).
2006;(144):1-113.
16. Cao P, Verzini F, Parlani G, et al. Clinical effect of
abdominal aortic aneurysm endografting: 7-year
concurrent comparison with open repair. J Vasc
Surg. 2004;40:841-848.
17. Eliason JL, Wainess RM, Dimick JB, et al. The
effect of secondary operations on mortality
following abdominal aortic aneurysm repair in the
United States: 1988-2001. Vasc Endovascular Surg.
2005;39:465-472.
18. Hobo R, Buth J, EUROSTAR collaborators.
Secondary interventions following endovascular
abdominal aortic aneurysm repair using current
endografts. A EUROSTAR report. J Vasc Surg.
2006;43:896-902.
19. Jones WB, Taylor SM, Kalbaugh CA, et al. Lost to
follow-up: A potential under-appreciated limitation
of endovascular aneurysm repair. J Vasc Surg.
2007;46:434-40; discussion 440-1.
20. Griffith S. A review of the factors associated with
patient compliance and the taking of prescribed
medicines. Br J Gen Pract. 1990;40:114-116.
21. Jacobson JA. The effect of patients' noncompliance
on their surgeons' obligations. Surg Clin North Am.
2007;87:937-48, viii.
22. Leurs LJ, Laheij RJ, Buth J, EUROSTAR
Collaborators. What determines and are the
consequences of surveillance intensity after

endovascular abdominal aortic aneurysm repair?
Ann Vasc Surg. 2005;19:868-875.
23. Weiss JS, Dumas P, Cha C, Gusberg RJ, Dardik A.
Safety of carotid endarterectomy in a high-risk
population: Lessons from the VA and Connecticut.
J Am Coll Surg. 2006;203:277-282.

